Last updated on February 2018

Afatinib and Selumetinib in Advanced KRAS Mutant and PIK3CA Wildtype Non-small Cell Lung Cancer


Brief description of study

This is a multi-center open-label proof-of-concept study consisting of two parts: PART A - a phase I dose-finding study (3 + 3 classical design) evaluating the RP2D of afatinib in combination with selumetinib in KRASm NSCLC; and PART B - a randomized phase II study investigating the progression free survival and safety of selumetinib/afatinib combination therapy compared to standard of care chemotherapy in KRASm NSCLC.

Clinical Study Identifier: NCT02450656

Contact Investigators or Research Sites near you

Start Over

Carla ML van Herpen, MD, ...

UMC St. Radboud Nijmegen
Nijmegen, Netherlands
  Connect »

J.H.M. Schellens, MD, PhD

Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital
Amsterdam, Netherlands
  Connect »